capecitabine has been researched along with everolimus in 24 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (4.17) | 29.6817 |
| 2010's | 19 (79.17) | 24.3611 |
| 2020's | 4 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Collingridge, D | 1 |
| Mehta, SP | 1 |
| Eriksson, B | 1 |
| Ahn, HK; Baek, KK; Han, B; Kang, WK; Kim, KM; Lee, DJ; Lee, HY; Lee, J; Lee, SJ; Lim, HY; Lim, T; Park, JO; Park, SH; Park, YS | 1 |
| Beijnen, JH; Deenen, MJ; Klümpen, HJ; Richel, DJ; Schellens, JH; Sparidans, RW; Weterman, MJ; Wilmink, JW | 1 |
| Klümpen, HJ; Kordes, S; Richel, DJ; Stevens, AJ; Weterman, MJ; Wilmink, JW | 1 |
| Kaklamani, V; Raffin, M; Reddy, S | 1 |
| Boeck, S; Haas, M; Heinemann, V; Holdenrieder, S; Kern, C; Nagel, D; Stieber, P; Wittwer, C | 1 |
| Do, IG; Jung, SH; Kang, WK; Kim, KM; Lee, J; Lee, SJ; Lim, HY; Park, JO; Park, SH; Park, YS; Yim, DS | 1 |
| Arrowood, CC; Bendell, JC; Brady, JC; Broderick, S; Cushman, SM; Dellinger, A; Hsu, SD; Hurwitz, HI; Kozloff, MF; Meadows, J; Meadows, KL; Morse, MA; Murphy, J; Nixon, AB; Pang, H; Rangwala, F; Starodub, AN; Starr, A; Strickler, JH; Tourt-Uhlig, S; Uronis, HE; Wallace, J; Zafar, SY | 1 |
| Do, IG; Kang, WK; Kim, KM; Kim, ST; Lee, J; Sohn, I | 1 |
| Klümpen, HJ; Kordes, S; Richel, DJ; Schellens, JH; Weterman, MJ; Wilmink, JW | 1 |
| Abdel-Rahman, O; Fouad, M | 1 |
| Fang, A; Guérin, A; Hao, Y; Kageleiry, A; Koo, V; Li, N; Peeples, M; Wu, EQ | 1 |
| Arnal, AV; Donovan, LE; Odia, Y; Wang, SH | 1 |
| Chen, M; Guardino, E; Sheth, S; Svahn, T; Vidal, GA | 1 |
| Blau, S; Burris, H; de Boer, RH; Ejlertsen, B; Ewertz, M; Fan, J; Hurvitz, S; Jerusalem, G; Kovalenko, E; Landherr, L; Louveau, AL; Noel-Baron, F; Özgüroglu, M; Taran, T; Yardley, DA | 1 |
| Chen, Z; Gong, C; Hu, S; Hu, X; Li, Y; Wang, B; Wang, L; Xie, Y; Yuan, P; Zhang, J; Zhang, Y; Zhao, Y | 1 |
| Beitler, JJ; Cardin, D; Cardona, K; Chakravarthy, AB; Chen, Z; El-Rayes, BF; El-Rifai, W; Fernandez, F; Force, S; Goff, L; Harvey, RD; Higgins, K; Krasinskas, A; Lambright, E; Landry, J; Nesbitt, J; Owonikoko, T; Pickens, A; Ramalingam, SS; Saba, NF; Salaria, S; Shin, DM; Staley, C; Willingham, F | 1 |
| Chiabudini, M; Decker, T; Falkenstein, J; Hagen, V; Hahn, A; Indorf, M; Klare, P; Kurbacher, CM; Maintz, C; Potthoff, K; Runkel, E; Sent, D; Söling, U; Vehling-Kaiser, U | 1 |
| Halfdanarson, TR; Leventakos, K; Molina, JR; Uprety, D | 1 |
| Colao, A; Faggiano, A; Ferraù, F; Lania, A; Modica, R; Rubino, M | 1 |
| Halfdanarson, TR; Kommalapati, A; Sonbol, MB; Starr, JS; Tella, SH | 1 |
7 review(s) available for capecitabine and everolimus
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Palliative chemotherapy for pancreatic malignancies.
Topics: Adenocarcinoma; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Deoxycytidine; ErbB Receptors; Erlotinib Hydrochloride; Everolimus; Fluorouracil; Gemcitabine; Humans; Immunosuppressive Agents; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Palliative Care; Pancreatic Neoplasms; Quality of Life; Quinazolines; Sirolimus | 2010 |
New drugs in neuroendocrine tumors: rising of new therapeutic philosophies?
Topics: Antineoplastic Agents; Capecitabine; Dacarbazine; Deoxycytidine; Drug Therapy; Everolimus; Fluorouracil; Humans; Indoles; Neuroendocrine Tumors; Octreotide; Pyrroles; Sirolimus; Sunitinib; Temozolomide; Treatment Outcome | 2010 |
Temozolomide-based combination for advanced neuroendocrine neoplasms: a systematic review of the literature.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Dacarbazine; Everolimus; Humans; Neuroendocrine Tumors; Octreotide; Temozolomide; Thalidomide | 2015 |
Pulmonary Neuroendocrine Tumors: Adjuvant and Systemic Treatments.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bronchial Neoplasms; Capecitabine; Carcinoid Tumor; Chemotherapy, Adjuvant; Cisplatin; Etoposide; Everolimus; Humans; Immune Checkpoint Inhibitors; Lung Neoplasms; Lymph Node Excision; Molecular Targeted Therapy; Neuroendocrine Tumors; Octreotide; Organometallic Compounds; Pneumonectomy; Protein Kinase Inhibitors; Radiopharmaceuticals; Receptors, Somatostatin; Somatostatin; Temozolomide; Watchful Waiting | 2020 |
Neoadjuvant Therapy for Neuroendocrine Neoplasms: Recent Progresses and Future Approaches.
Topics: Capecitabine; Chemoradiotherapy; Disease Progression; Disease-Free Survival; Everolimus; Humans; Neoadjuvant Therapy; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neuroendocrine Tumors; Pancreatic Neoplasms; Quality of Life; Radioisotopes; Somatostatin; Temozolomide; Treatment Outcome | 2021 |
Management of well-differentiated neuroendocrine tumors.
Topics: Antineoplastic Agents; Capecitabine; Everolimus; Humans; Neuroendocrine Tumors; Pancreatic Neoplasms; Somatostatin | 2021 |
12 trial(s) available for capecitabine and everolimus
| Article | Year |
|---|---|
Phase I trial of capecitabine plus everolimus (RAD001) in patients with previously treated metastatic gastric cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Disease-Free Survival; Drug Resistance, Neoplasm; Everolimus; Female; Fluorouracil; Humans; Male; Maximum Tolerated Dose; Middle Aged; Sirolimus; Stomach Neoplasms; Treatment Outcome | 2011 |
Phase I and pharmacokinetic study of capecitabine and the oral mTOR inhibitor everolimus in patients with advanced solid malignancies.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Capecitabine; Deoxycytidine; Dose-Response Relationship, Drug; Everolimus; Female; Fluorouracil; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Neoplasms; Protein Kinase Inhibitors; Sirolimus; TOR Serine-Threonine Kinases; Young Adult | 2012 |
A phase I/II, non-randomized, feasibility/safety and efficacy study of the combination of everolimus, cetuximab and capecitabine in patients with advanced pancreatic cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cetuximab; Deoxycytidine; Everolimus; Feasibility Studies; Female; Fluorouracil; Humans; Male; Middle Aged; Pancreatic Neoplasms; Sirolimus; Treatment Outcome | 2013 |
Cytokeratin 19-fragments (CYFRA 21-1) as a novel serum biomarker for response and survival in patients with advanced pancreatic cancer.
Topics: Adult; Aged; Albumins; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Biomarkers, Tumor; CA-19-9 Antigen; Capecitabine; Carcinoembryonic Antigen; Deoxycytidine; Disease-Free Survival; Erlotinib Hydrochloride; Everolimus; Fluorouracil; Gemcitabine; Humans; Imidazoles; Indazoles; Keratin-19; Middle Aged; Multivariate Analysis; Oximes; Paclitaxel; Palliative Care; Pancreatic Neoplasms; Piperazines; Prospective Studies; Quinazolines; Sirolimus; Sulfonamides; Survival Rate | 2013 |
Phase II trial of capecitabine and everolimus (RAD001) combination in refractory gastric cancer patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Drug Resistance, Neoplasm; Everolimus; Female; Fluorouracil; Humans; Male; Middle Aged; Sirolimus; Stomach Neoplasms; Young Adult | 2013 |
Phase I study of capecitabine, oxaliplatin, bevacizumab, and everolimus in advanced solid tumors.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Capecitabine; Deoxycytidine; Everolimus; Female; Fluorouracil; Humans; Immunosuppressive Agents; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Neuropilin-1; Neuropilin-2; Organoplatinum Compounds; Oxaliplatin; RNA, Messenger; Sirolimus; Vascular Endothelial Growth Factor A | 2014 |
The NanoString-based multigene assay as a novel platform to screen EGFR, HER2, and MET in patients with advanced gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Capecitabine; Everolimus; Female; Genes, erbB-1; Genes, erbB-2; High-Throughput Nucleotide Sequencing; Humans; Immunohistochemistry; In Situ Hybridization, Fluorescence; Male; Middle Aged; Proto-Oncogene Proteins c-met; ROC Curve; Salvage Therapy; Sensitivity and Specificity; Sequence Analysis, RNA; Stomach Neoplasms | 2015 |
Phase II study of capecitabine and the oral mTOR inhibitor everolimus in patients with advanced pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Disease-Free Survival; Everolimus; Female; Fluorouracil; Humans; Male; Middle Aged; Pancreatic Neoplasms; Protein Kinase Inhibitors; Sirolimus; Survival Rate; TOR Serine-Threonine Kinases | 2015 |
Phase I Trial of Everolimus and Capecitabine in Metastatic HER2
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Disease-Free Survival; Dose-Response Relationship, Drug; Everolimus; Female; Humans; Maximum Tolerated Dose; Middle Aged; Treatment Outcome | 2017 |
Everolimus Plus Exemestane vs Everolimus or Capecitabine Monotherapy for Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer: The BOLERO-6 Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Everolimus; Female; Humans; Kaplan-Meier Estimate; Middle Aged; Receptor, ErbB-2; Receptors, Estrogen; Treatment Outcome | 2018 |
Phase IB Study of Induction Chemotherapy With XELOX, Followed by Radiation Therapy, Carboplatin, and Everolimus in Patients With Locally Advanced Esophageal Cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Capecitabine; Carboplatin; Chemoradiotherapy; Esophageal Neoplasms; Everolimus; Female; Follow-Up Studies; Humans; Induction Chemotherapy; Male; Middle Aged; Paclitaxel; Prognosis; Prospective Studies | 2019 |
Final results from IMPROVE: a randomized, controlled, open-label, two-arm, cross-over phase IV study to determine patients' preference for everolimus in combination with exemestane or capecitabine in combination with bevacizumab in advanced HR-positive, H
Topics: Aged; Aged, 80 and over; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Capecitabine; Cross-Over Studies; Estrogen Receptor alpha; Everolimus; Female; Humans; Middle Aged; Patient Preference; Prognosis; Quality of Life; Receptor, ErbB-2; Receptors, Progesterone; Survival Rate; Treatment Outcome | 2020 |
5 other study(ies) available for capecitabine and everolimus
| Article | Year |
|---|---|
San Antonio Breast Cancer Symposium.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Docetaxel; Epothilones; Everolimus; Female; Fluorouracil; Humans; Letrozole; Nitriles; Sirolimus; Tamoxifen; Taxoids; Trastuzumab; Triazoles | 2008 |
Targeting angiogenesis in metastatic breast cancer.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Capecitabine; Clinical Trials, Phase III as Topic; Deoxycytidine; Disease-Free Survival; Everolimus; Female; Fluorouracil; Humans; Indoles; Neoplasm Metastasis; Neovascularization, Pathologic; Niacinamide; Paclitaxel; Phenylurea Compounds; Pyrroles; Sirolimus; Sorafenib; Sunitinib; TOR Serine-Threonine Kinases; Vascular Endothelial Growth Factor A | 2012 |
Time on treatment of everolimus and chemotherapy among postmenopausal women with hormone-receptor-positive/human-epidermal-growth-factor-receptor-2-negative metastatic breast cancer: a retrospective claims study in the US.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Everolimus; Female; Humans; Kaplan-Meier Estimate; Middle Aged; Postmenopause; Proportional Hazards Models; Receptor, ErbB-2; Retrospective Studies | 2016 |
Widely metastatic atypical pituitary adenoma with mTOR pathway STK11(F298L) mutation treated with everolimus therapy.
Topics: Adenoma; Adrenocorticotropic Hormone; AMP-Activated Protein Kinase Kinases; Antineoplastic Agents; Brain; Brain Neoplasms; Capecitabine; Dacarbazine; Everolimus; Female; Humans; Ki-67 Antigen; Magnetic Resonance Imaging; Middle Aged; Mutation; Pituitary Neoplasms; Protein Serine-Threonine Kinases; Temozolomide | 2016 |
Treatment after Progression on Fulvestrant among Metastatic Breast Cancer Patients in Clinical Practice: a Multicenter, Retrospective Study.
Topics: Adult; Aged; Aged, 80 and over; Androstadienes; Breast Neoplasms; Capecitabine; Disease Progression; Everolimus; Female; Fulvestrant; Humans; Middle Aged; Multivariate Analysis; Neoplasm Metastasis; Receptor, ErbB-2; Retrospective Studies; Risk Factors; Survival Analysis; Treatment Outcome | 2019 |